Cover Image

Accounting for Carryover Toxicity in Phase I Clinical Trials with Intra‐Patient Dose Escalation

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Chloe E. Falke, Joseph S. Koopmeiners
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Statistics in Medicine
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Dose Individualization for Phase I Cancer Trials With Broadened Eligibility
by: Rebecca B. Silva, et al.
Published: (2024)

A Phase I Dose‐Finding Design Incorporating Intra‐Patient Dose Escalation
by: Beibei Guo, et al.
Published: (2024)

Testing for Similarity of Dose Response in Multiregional Clinical Trials
by: Holger Dette, et al.
Published: (2025)

Bayesian Ordered Lattice Design for Phase I Clinical Trials
by: Gi‐Ming Wang, et al.
Published: (2026)

Towards Efficient Time‐to‐Event Dose‐Escalation Guidance of Multi‐Cycle Cancer Therapies
by: Lukas A. Widmer, et al.
Published: (2025)

A Generalized Phase I/II Dose Optimization Trial Design With Multi‐Categorical and Multi‐Graded Outcomes
by: Yichen Yan, et al.
Published: (2025)

Defining Utility as a Measure of Preference Under Uncertainty in Phase I– II Oncology Dose Finding Trials
by: Andrew Hall, et al.
Published: (2026)

On Inclusion of Covariates in Model Based Dose Finding Clinical Trial Designs
by: Adrien Ollier, et al.
Published: (2025)

Patient‐Centric Pragmatic Clinical Trials: Opening the DOOR
by: Scott R. Evans, et al.
Published: (2026)

Adaptive Biomarker‐Based Design for Early Phase Clinical Trials
by: Alessandra Serra, et al.
Published: (2025)

A Bayesian Treatment Selection Design for Phase II Randomised Cancer Clinical Trials
by: Moka Komaki, et al.
Published: (2026)

A Biomarker‐Based Dose–Schedule Optimization Design for Immunotherapy Trials
by: Yingjie Qiu, et al.
Published: (2026)

Futility Monitoring in Clinical Trials
by: Ana M. Ortega‐Villa, et al.
Published: (2025)

An Empirical Assessment of the Cost of Dichotomization of the Outcome of Clinical Trials
by: Erik W. van Zwet, et al.
Published: (2026)

Sample Size Calculation in Dose Optimization Trials Using the Margin of Practical Non‐Inferiority
by: Hakim‐Moulay Dehbi, et al.
Published: (2025)

Exact Randomized Two‐Stage Phase 2 Clinical Trial Designs for Two Binary Co‐Primary Endpoints
by: Hyejung Jung, et al.
Published: (2026)

The Win Ratio Approach in Bayesian Monitoring for Two‐Arm Phase II Clinical Trial Designs With Multiple Time‐To‐Event Endpoints
by: Xinran Huang, et al.
Published: (2024)

RMST for Interval‐Censored Data in Oncology Clinical Trials
by: Xiyuan Gao, et al.
Published: (2025)

Dynamic Borrowing From Historical Controls via the Synthetic Prior With Covariates in Randomized Clinical Trials
by: Daniel E. Schwartz, et al.
Published: (2026)

Response‐Adaptive Randomization Procedure in Clinical Trials with Surrogate Endpoints
by: Jingya Gao, et al.
Published: (2024)

Preference‐Informed Cluster Randomized Design for Pragmatic Clinical Trials
by: Yuwei Cheng, et al.
Published: (2026)

Accounting for Patient Characteristics in a Model‐Based Kappa of Agreement Between Two Experts' Ordinal Ratings
by: Kerrie P. Nelson, et al.
Published: (2025)

A Biomarker Signature‐Guided Clinical Trial Design for Precision Medicine
by: Yuan Li, et al.
Published: (2025)

Clinical Trial Simulation: Planning With the OCTAVE Framework, Implementation and Validation Principles
by: Kim May Lee, et al.
Published: (2026)

DOD ‐ SSR : An Adaptive Seamless Phase II / III Design With Dose Optimization Decision and Sample Size Re‐estimation
by: Meizi Liu, et al.
Published: (2025)

Sequential Monitoring of Covariate‐Adaptive Randomized Clinical Trials With Non‐Parametric Approaches
by: Xiaotian Chen, et al.
Published: (2025)

A Saddlepoint Framework for Accurate Inference in Multicenter Clinical Trials With Imbalanced Clusters
by: Haidy A. Newer
Published: (2026)

Accounting for Misclassification of Cause of Death in Weighted Cumulative Incidence Functions for Causal Analyses
by: Jessie K. Edwards, et al.
Published: (2025)

Bayesian Safety and Futility Monitoring in Phase II Trials Using One Utility‐Based Rule
by: Juhee Lee, et al.
Published: (2024)

Matching‐Assisted Power Prior for Incorporating Real‐World Data in Randomized Clinical Trial Analysis
by: Ruoyuan Qian, et al.
Published: (2025)

Doubly Robust Estimation and Sensitivity Analysis With Outcomes Truncated by Death in Multi‐Arm Clinical Trials
by: Jiaqi Tong, et al.
Published: (2025)

Synergy Area With FDR ‐Controlled Evaluation ( SAFE ) to Robustly Assess Safety Profile in Clinical Trials
by: Tianyu Zhan, et al.
Published: (2026)

BAR12 : Bayesian Autoregressive Phase 1‐2 Design for Cell Therapy Trials With Manufacturing Changes
by: Cheng‐Han Yang, et al.
Published: (2026)

Cumulative Logit Ordinal Regression With Proportional Odds Under Nonignorable Missing Responses—Application to Phase III Trial
by: Arnab Kumar Maity, et al.
Published: (2025)

Balancing Events, Not Patients, Maximizes Power of the Logrank Test: And Other Insights on Unequal Randomization in Survival Trials
by: Godwin Yung, et al.
Published: (2025)

Negative Control Outcome Adjustment in Early‐Phase Randomized Trials: Estimating Vaccine Effects on Immune Responses in HIV Exposed Uninfected Infants
by: Ethan Ashby, et al.
Published: (2025)

Design and Analysis of N‐Of‐1 Trials That Incorporate Sequential Monitoring
by: Shu Jiang, et al.
Published: (2025)

The Cox Model With Adaptive Fused Group Bridge Penalty to Incorporate Historical Data Into the Analysis of Clinical Trials With an Application to BMT CTN 1101
by: Xi Fang, et al.
Published: (2025)

Estimating Risk Factors for Pathogenic Dose Accrual From Longitudinal Data
by: Daniel K. Sewell, et al.
Published: (2025)

Active‐Controlled Trial Design for HIV Prevention Trials With a Counterfactual Placebo
by: Fei Gao, et al.
Published: (2025)